



Op. 185
#14
E-f.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
REDDY, Vermuri B. et al
Serial No.: 07/323,665
Filed: April 24, 1989
For: FSH

Art Unit: 184
Examiner: Wang, G.
Washington, D.C.
June 17, 1991

RECEIVED GROUP 180

JUL 23 1991

TERMINAL DISCLAIMER

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:


Genzyme Corporation, having a principal place of business at 75 Kneeland Street, Boston, MA 02111 (hereinafter "Genzyme") is the assignee of the entire right, title and interest of the above-identified patent application by virtue of an assignment recorded March 30, 1990, at Reel 5268, Frame 0958. Genzyme hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of United States Patent No. 4,923,805, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to United States Patent No. 4,923,805, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns. Genzyme does not disclaim any terminal part of any patent

Serial No. 07/323,665

granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent No. 4,923,805 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(1), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term, except for the separation of legal title stated above. This terminal disclaimer is being made without waiver of petitioner's rights under 35 U.S.C. 156 which may be available to extend the term of any patent granted on the above-identified application beyond the date set by this terminal disclaimer (37 CFR 1.775(a)). A charge form for payment of the fee required by 37 CFR 1.20(d) is attached hereto.

Genzyme Corporation

By:


signature

Mark A. Hofer, Esq.

Typed Name of Signatory

Assistant Secretary

Vice President, General Counsel

Title

7/12/91
Date